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Abstract  
 
Objectives: Two studies examined the pharmacokinetics of indinavir and rifabutin 
when coadministered in healthy subjects.  Rifabutin, which induces expression of 
cytochrome P450 (CYP) 3A, and indinavir, which inhibits that enzyme system, are 
frequently coadministered in patients infected with HIV.  The second study was 
undertaken to determine if altering the dose of rifabutin coadministered with 
indinavir would minimize the drug interaction observed in the first study. Methods: 
Two studies, each with a three period crossover design,, were performed.  In study 
1, standard doses of rifabutin and indinavir (300 mg of rifabutin qd and 800 mg 
indinavir q8h) were administered as monotherapy (with placebo to the other drug) 
or in combination to 10 volunteers for ten days.  In study 2, 150 mg qd of rifabutin 
together with 800 mg q8h of indinavir, 300 mg qd of rifabutin alone, or 800 mg q8h 
of indinavir alone was administered to 14 volunteers for ten days. 
Results: In study 1, the geometric mean ratio (GMR) (90% CI) of the AUC(0-8 hr) of 
indinavir, coadministered with rifabutin 300 mg qd compared to indinavir alone (with 
rifabutin placebo), was 0.66 (0.56, 0.77) while that of the AUC(0-24 hr)  of rifabutin, 
coadministered with indinavir compared to rifabutin alone (with indinavir placebo), 
was 2.73 (1.99, 3.77).  In study 2, the GMR (90% CI) of the AUC(0-8 hr) of indinavir, 
coadministered with rifabutin 150 mg qd compared to indinavir alone, was 0.68 
(0.60, 0.76) while that of the AUC(0-24 hr)  of rifabutin, when rifabutin 150 mg qd was 
coadministered with indinavir compared to rifabutin 300 mg qd alone , was 1.54 
(1.33, 1.79).  For both Studies 1 and 2, indinavir and rifabutin administered alone 
or in combination were generally well-tolerated.  No clinical or laboratory adverse 
experience was serious. 
Conclusions: These data demonstrate the important pharmacokinetic interactions 
between indinavir and rifabutin when they are coadministered.  Indeed, these 
observations formed the basis for the subsequent ACTG 365 study that explored 
dose adjustments for these agents in combination regimens in order to preserve 
the sustained antiviral activity of indinavir in the absence of adverse events as a 
result of elevated circulating levels of rifabutin. 
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INTRODUCTION 
Optimal therapy for HIV infection incorporates the use of a combination of antiviral 
medications.  Indinavir is a potent antiretroviral of the protease inhibitor class.  
Specifically, it inhibits HIV-1 aspartyl protease1 and thereby prevents the cleavage 
of HIV pol-gag polypeptides.  As a result of inhibition of this enzyme, the HIV viral 
particles released from infected human cells are noninfectious.2  Indinavir has been 
employed as one component of Highly Active Antiretroviral Therapy (HAART), the 
strategy of using combinations of potent antiretroviral agents to produce durable 
reductions in HIV viral load.3,4 
The use of HAART has significantly reduced the incidence of infections due to 
opportunistic organisms in patients infected with HIV.  However, chemoprophylaxis 
remains an important part of the care of HIV infected individuals and has survival 
benefit, even in patients receiving HAART.5  Since disseminated infection with 
Mycobacterium avium complex (MAC) may occur with advanced 
immunosuppression, the 2001 USPHS/IDSA guideline recommends primary 
prophylaxis against MAC when the CD4 count falls below 50 cells/L.6  The 
macrocyclic antibiotic rifabutin is an alternate agent for use in MAC prophylaxis, 
and has a role in the treatment of disseminated disease.7  Additionally, the CDC 
guideline for treatment of tuberculosis in patients infected with HIV endorses the 
substitution of rifabutin for rifampin in those patients who receive protease 
inhibitors, as rifabutin causes less induction of drug metabolizing cytochromes than 
rifampin.8  
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Indinavir is primarily metabolized by the cytochrome P450 isoenzyme 3A4 
(CYP3A4); it also inhibits CYP3A4.9  Rifabutin is also metabolized by hepatic 
CYP3A4, but induces its activity.10  Since coadministration of rifabutin and indinavir 
is common in treating patients infected with HIV, and each drug has an effect on, 
and is metabolized by, CYP3A4, it is reasonable to predict some degree of 
interaction between these two drugs.  Evaluation of their pharmacokinetics 
individually and when coadministered would help define an optimal combination 
therapy for treatment of patients infected with HIV.  Therefore, the first study 
examined the pharmacokinetics of indinavir and rifabutin when coadministered and 
the second study was undertaken to determine if altering the dose of rifabutin 
coadministered with indinavir would minimized the drug interaction observed in the 
first study. 
METHODS 
Both of the two studies described herein were performed in the Clinical Research 
Unit at the Thomas Jefferson University Hospital in Philadelphia, Pennsylvania. 
Subjects 
Ten healthy male subjects (5 Caucasian, 4 Black, 1 Hispanic) completed Study 1 
and fourteen healthy subjects (12 male; 8 Caucasian and 4 Black, 2 female; both 
Caucasian) completed Study 2..  All subjects were non-smokers between 21 and 
41 years of age.  All were within 20% of their ideal body weight, and were judged 
to be in good health based on history, physical examination, and laboratory 
examination (complete blood count, serum electrolytes, creatinine, liver function 
tests, HIV test and urinalysis).  Subjects with a history of nephrolithiasis, positive 
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hepatitis B surface antigen, or liver disease, or elevations in total or direct bilirubin 
were excluded.  Subjects who have consumed excessive alcoholic (more than two 
drinks) and/or caffeine (more than 6-12 oz drinks) containing beverages per day or 
subjects who have used any prescription medication within 14 days of the study 
especially rifampin, triazolam, midazolam, astemizole, or cisapride or any non 
prescription medications within 7 days of study start of the study or subjects who 
donated blood or participated in another clinical trial within the last 4 weeks, or 
subjects who were regular users of illicit drug or a history of drug or alcohol abuse 
were excluded.  All subjects provided written informed consent prior to participation 
in these clinical studies.  All protocols were reviewed and approved by the 
Institutional Review Board of Thomas Jefferson University. 
Study Design 
Both studies were multiple-dose, randomized, three period crossover studies.  
Subjects received, in randomized order, three different treatments, each for 10 
days, as described below.  Given that rifabutin and indinavir were generally well 
tolerated as seen in study 1, and a smaller dose of rifabutin was used, placebo was 
not administered in study 2.  All study drugs were administered by witnessed 
dosing.  All study drugs were supplied by Merck Research Laboratories, Inc.  For 
Study 1 the placebo for rifabutin grossly matched active rifabutin.  
Study 1: Treatment A consisted of indinavir 800 mg q8h (4 x 200 mg capsules) and 
rifabutin placebo, treatment B consisted of rifabutin 300 mg qd (2 x 150 mg 
capsules) and indinavir placebo, and treatment C consisted of indinavir 800 mg q8h 
and rifabutin 300 mg qd.  Rifabutin was administered at the same time of day for 
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each subject.  On Day 10 of each period indinavir/placebo was administered for 3 
doses (q8h).  Each period of treatment was separated by at least a 10 days.  
Venous blood samples for the determination of plasma indinavir were collected at 
time 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 8 hours after the morning dose of 
indinavir on the morning of Day 10 for both treatments A and C.  Venous blood 
samples for the determination of plasma rifabutin and 25-O-desacetyl rifabutin, the 
active metabolite of rifabutin,11 were collected at time 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 
16, and 24 hours after the administration of the last dose of rifabutin on the morning 
of Day 10 for treatments B and C.  Liver function tests were performed 4 hours after 
the last dose of drug, and safety labs (complete blood count, serum electrolytes 
and creatinine and urinalysis) and physical examination were performed 24 hours 
after the last dose of drug. 
Study 2: The dose of rifabutin was decreased to 150 mg when coadministered with 
indinavir.  Subjects in treatment D received indinavir 800 mg q8h, those in treatment 
E received rifabutin 300 mg qd, and those in treatment F received indinavir 800 mg 
q8h and rifabutin 150 mg qd.  Rifabutin was administered at the same time of day 
for each subject.  On Day 10 (Treatment D and F), indinavir was administered for 
three doses (q8h).  Concentrations of indinavir, rifabutin, and 25-O-desacetyl 
rifabutin were determined in samples of venous blood obtained at various intervals, 
as described for Study 1. 
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Analytical Methods 
For both studies, plasma concentrations of indinavir12, rifabutin, and 25-desacetyl-
rifabutin were each determined using high-performance liquid chromatographic 
methods with ultraviolet detection. 
For study 1 indinavir was assayed by Merck Research Laboratories (MRL) as 
previously described12 except that the standard curve range was 25-5000 ng/mL.  
The assay limit of quantitation was 25 ng/ml (40.7 nM).  Mean intra-day accuracy 
and precision (n=5) ranged from 97.6-105.0% and 1.1-3.4%, respectively,  Inter-
day precision of QC samples was 2.25% at 75 ng/mL and 0.93% at 3500 ng/mL  
Rifabutin and 25-O-desacetyl rifabutin were assayed by MDS-Pharma (Lincoln, 
Nebraska) using a proprietary method.   Briefly, the assay method consisted of 
liquid-liquid extraction of drug, metabolite and internal standard into an organic 
solution (hexane:ethyl acetate) followed by separation and evaporation of the 
organic layer.  The residue was reconstituted in a small volume and injected onto 
and HPLC system with UV detection at 275 nm.  The assay limit of quantitation was 
5 ng/ml for rifabutin and 2.5 ng/ml for 25-O-desacetyl rifabutin.  Replicated 
standards (n=5) were all accurate to within 7.4% of nominal values and the 
coefficients of variation were all less than 8.6% for both analytes.  For inter-day 
precision of QC samples was 5.9% at 10 ng/mL and 2.9% at 400 ng/mL for rifabutin 
and 4.1% at 5 ng/mL and 2.4% at 200 ng/mL for -O-desacetyl rifabutin,  
For study 2 indinavir, rifabutin and its 25-desacetyl metabolite were assayed by 
BAS Analytics (West Lafayette, Indiana).  Indinavir was assayed as previously 
described12 except that the last liquid-liquid extraction step was omitted and the 
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calibration curve range was 12-15,000 ng/mL. The indinavir assay limit of 
quantitation was 12 ng/mL (19.5 nM). Accuracy and precision ranged from 98.3-
107.2% and 4.3-5.6%, respectively.  Inter-day precision of QC samples was 10.4% 
at 50 ng/mL, 4.1% at 1,000 ng/mL and 8.5% at 10,000 ng/mL.  For rifabutin and 
25-O-desacetyl rifabutin, the assay was comprised of liquid-liquid extraction into n-
butylchloride followed by separation and evaporation of the organic layer.  The 
residue was reconstituted in an aqueous solution containing 32% acetonitrile and 
0.2% trifluoroacetic acid followed by liquid-liquid extraction with hexane.  The 
aqueous phase was then injected onto an HPLC system with UV detection at 275 
nm.  The assay limit of quantitation was 5 ng/mL for rifabutin and 3.7 ng/mL for 25-
O-desacetyl rifabutin.  For rifabutin, mean accuracy and precision ranged from 
94.9-103.7% and 2.1-11.7%, respectively.  Inter-day precision of QC samples was 
10.4% at 10 ng/mL, 3.5% at 80 ng/mL and 2.9% at 400 ng/mL.  For 25-O-desacetyl 
rifabutin, mean accuracy and precision ranged from 98.8-101.4% and 1.3-8.8%, 
respectively.  Inter-day precision of QC samples was 7.0% at 5 ng/mL, 3.4% at 40 
ng/mL and 2.3% at 200 ng/mL. 
Assays in both studies were checked for cross-interference by assaying plasma 
samples from treatments where only the non-assayed drug was administered.  For 
both studies, indinavir concentrations were converted to a molar basis by using a 
molecular weight of 613.81. 
Pharmacokinetic Analysis 
For both studies, peak plasma concentration, Cmax, time to peak concentration, 
Tmax, and area under the concentration-time curve over the final dosing interval, 
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AUC(0-8 hr) for indinavir and AUC(0-24 hr) for rifabutin and its metabolite, were 
determined for each treatment in which the respective drugs were administered. 
Cmax and Tmax, were obtained directly from the concentration-time data.  AUC was 
calculated by a modified trapezoidal rule using piecewise cubic polynomials.13  
Actual sample times recorded by the investigator were used to calculate AUC.  
Trough plasma concentration, C8hr, also was assessed for indinavir.  All 
concentrations below the limit of quantitation were treated as zeroes for 
pharmacokinetic calculations.  Excel (Microsoft, Redmond, WA) was the software 
used for this analysis. 
Statistical Analysis 
 
Power: 
For Study 1, as the primary objective was to evaluate the effect of rifabutin on the 
pharmacokinetics of indinavir, this study was powered for indinavir only.  (The large 
effect seen of indinavir on rifabutin was unexpected in this early study).  To address 
the primary objective of the effect of rifabutin on the AUC of indinavir the MSE=0.13 
(on the log scale) was estimated from a previous early clinical trial using 600 mg 
q8h (data on file).  Given a three-period crossover study with n=12 subjects and a 
type I error = 0.05 and assuming similar variation of indinavir and rifabutin, there 
was a 99% probability that the observed 90% confidence interval for the ratio of 
geometric mean AUC (indinavir and rifabutin/indinavir alone) will fall within the 
equivalence interval (0.5, 2.0), if the true ratio 1.0.  There was 80% probability that 
the 90% confidence interval would fall within the equivalence interval (0.64, 1.56), 
if the true ratio was 1. 
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For Study 2, the objectives were to evaluate both the effect of rifabutin on indinavir 
and indinavir on rifabutin with an adjusted rifabutin dose.  For this study, data (MSE) 
from study 1 were used in the power calculations as follows.  In study 1, the 
observed AUC ratio of rifabutin when rifabutin was administered with indinavir 
relative to rifabutin 300 mg alone was 2.73.  It seemed reasonable to assume based 
on these results that the AUC ratio of rifabutin with half the dose, relative to rifabutin 
alone could be as high as 1.37.  Therefore if the true ratio was 1.37 given the same 
three-period design with 15 subjects there was 83% probability that the observed 
90% confidence interval the ratio of geometric mean AUCs (combination/ rifabutin 
alone) could fall within the equivalence interval (0.50, 2.0).  For the effect of rifabutin 
on indinavir, the MSE = 0.034 (on the log scale) was used.  Given the same three-
period crossover design with 15 subjects, a type I error = 0.05 and a similar variation 
as seen in study 1, there was 99% probability that the observed 90% CI for the ratio 
of the geometric mean AUCs (combination/indinavir alone) would fall within the 
equivalence interval (0.5, 2.0) assuming the true ratio was 1.0. 
 
Methods: 
Although the clinical design of both studies were a standard three period crossover, 
the usual linear model (and the consequent ANOVA analysis) with subject, period, 
treatment and carryover effects entered as independent variables was modified to 
accommodate the following particular feature of these drug interaction trials.  Unlike 
a conventional three period crossover study, in these studies subjects receiving 
indinavir alone provide no data for assessing the effect of coadministration of 
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rifabutin with indinavir on the pharmacokinetics of rifabutin.  This assessment 
involves only a comparison of two of the three treatment groups, i.e., rifabutin 150 
mg and indinavir combined versus rifabutin 300 mg alone.  Similarly, subjects 
receiving rifabutin 300 mg alone provide no data for assessing the effect of 
coadministration of rifabutin 150 mg with indinavir on the pharmacokinetics of 
indinavir.  To account for this, a classification variable called 'pair' was defined to 
capture the variability due to the different pairs of periods in which two treatments 
were compared.  This variable 'pair' is based on a model proposed by Ciminera et 
al.14  It was of interest to test whether the treatment comparisons varied across the 
three different pairs, i.e., the treatment by pair interaction.  The interaction was 
tested using the contrast proposed by Ciminera et al., through the use of a modified 
three period ANOVA model on log-transformed data.  The modified ANOVA model 
initially contained terms for subject, period, treatment, carryover, and period by 
carryover interaction.  A contrast containing both carryover and period by carryover 
effects15 was run to test the treatment by pair interaction.  In the case of a non 
significant interaction (p>0.05), a second ANOVA model was run in which the 
carryover and period by carryover terms were dropped from the model.  A 90% 
confidence interval was constructed about the treatment differences using the 
results of the ANOVA.  In both studies, the treatment by pair interaction was found 
to be non significant, therefore no interaction terms were included in the final 
models.  .  The antilogs of the upper and lower limits were then calculated to obtain 
the confidence interval for the ratio of geometric means.  SAS version 6.12 (SAS 
Institute, Cary, NC) was used to analyze the data. 
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Results 
Study 1: Coadministration of Indinavir 800 mg q8h and Rifabutin 
300 mg daily  
Thirteen healthy male subjects with a mean age of 29.5 yr (range 22-41) and weight 
of 79.5 kg (range 60.8-101.8) enrolled in the study. Three subjects were 
discontinued; one due to a laboratory adverse experience considered drug related 
(see Safety), one due to a clinical adverse experience considered not drug related, 
while another subject withdrew consent to further participate during the third period.  
Data from all 13 subjects who enrolled were included in the safety analysis and 
data from the 10 subjects who completed the study were included in the 
pharmacokinetic analysis. 
Plasma profiles of indinavir were consistently lower when indinavir was 
administered with rifabutin (Fig. 1).  The AUC(0-8h), Cmax and C8h of indinavir were 
lower when coadministered with rifabutin 300 mg daily (Table I).  For AUC(0-8h), the 
geometric mean ratio (90% C.I.) for combination/monotherapy was 0.66 (0.56, 
0.77).  For C8h, the geometric mean ratio (90% C.I.) was 0.61 (0.50, 0.75).  The 
arithmetic means of indinavir Tmax with and without rifabutin were identical at 0.8 ± 
0.2 hours.  Conversely, plasma concentrations of rifabutin (Fig. 2) and its 25-
desacetyl metabolite (Fig. 3) were increased upon coadministration of rifabutin and 
indinavir.  The point estimates for the geometric mean AUC(0-24h) and Cmax for 
rifabutin increased more than 2-fold when coadministered with indinavir (Table II).  
The AUC(0-24h) and Cmax of 25-desacetyl rifabutin were similarly increased when 
coadministered with indinavir (Table II). 
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These observations were indicative of a clinically important pharmacokinetic 
interaction upon coadministration of indinavir and rifabutin.  The decreased plasma 
concentrations of indinavir were considered clinically significant due to the 
propensity of HIV to develop resistance in the face of decreased concentrations of 
protease inhibitors.  Conversely, the increases in circulating rifabutin 
concentrations were considered clinically significant due to a potential increase in 
concentration dependent toxicity.  Consequently, Study 2 was undertaken to 
determine if altering the dose of rifabutin coadministered with indinavir could 
minimize the drug interaction observed in Study 1. 
Study 2: Comparison of Rifabutin 150 mg Daily Coadministered 
with Indinavir 800 mg q8h and Rifabutin 300 mg Daily Alone 
Sixteen healthy male and four healthy female subjects with a mean age of 28.3 yrs 
(20-40) and mean weight of 70.5 kg (50.5-96.8) began the study.  Six subjects were 
discontinued from the study; 4 subjects were discontinued for personal reasons not 
related to study drug and 2 subjects discontinued due to adverse experiences 
considered drug-related by the investigator (see Safety).  Data from all 20 subjects 
who were enrolled in the study were included in the safety analysis.  Data from the 
14 subjects who completed the study were included in the pharmacokinetic 
analysis. 
Plasma profiles of indinavir were decreased when indinavir was coadministered 
with 150 mg rifabutin (Fig. 4) to an extent that was similar to that observed with the 
coadministration with 300 mg rifabutin (Study 1, Figure 1).  Coadministration with 
rifabutin 150 mg daily resulted in a decrease in the AUC(0-8h), Cmax and C8h of 
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indinavir (Table III).  For AUC(0-8h), the geometric mean ratio (90% C.I.) for 
combination/monotherapy was 0.68 (0.60, 0.76).  For C8h, the geometric mean ratio 
(90% C.I.) was 0.60 (0.51, 0.72).  The arithmetic means of indinavir Tmax with and 
without rifabutin were 0.9 ± 0.4 hours and 1.3 ± 0.9 hours, respectively. 
Plasma concentrations of rifabutin (Fig. 5) and 25-desacetyl-rifabutin (Fig. 6) were 
higher when 150 mg rifabutin was coadministered with indinavir compared to 
plasma concentrations of these analytes when 300 mg rifabutin was administered 
alone.  The geometric mean ratio (90% C.I.) for AUC(0-24h)  in the combination vs. 
monotherapy arms was 1.54 (1.33, 1.79), and for Cmax was 1.29 (1.05, 1.59) (Table 
IV).  Similarly, the AUC(0-24h) and Cmax of 25-desacetyl rifabutin were higher when 
rifabutin 150 mg was coadministered with indinavir compared to rifabutin 300 mg 
alone (Table IV).  The geometric mean ratio was 4.1 for AUC(0-24h), and 2.4 for Cmax.  
The arithmetic mean of rifabutin Tmax with and without indinavir was identical at 3.5 
± 1.0 hours.  The arithmetic mean of 25-desacetyl rifabutin Tmax with and without 
indinavir was 3.5 ± 1.4 hours and 3.9 ± 0.9 hours, respectively. 
Safety and Tolerability 
The combinations of Indinavir 800 mg q8h and rifabutin at either 300 mg daily or 
150 mg daily were generally well-tolerated.  There were no serious adverse events 
in either study.  
In Study 1, 4 of 11 subjects had clinical adverse experiences which were mild and 
possibly related to study drug.  Taste perversion was the most common drug-
related clinical adverse experience and occurred on indinavir alone, on indinavir 
and rifabutin, and on rifabutin alone.   
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Two of 3 subjects had laboratory adverse experiences which were judged possibly 
related to the study drug.  One subject had liver function and hematologic 
abnormalities and was discontinued from the study.  He had an increase in ALT 
while on indinavir alone, an increase in AST while on indinavir and rifabutin, and 
increases in ALT and AST while off drug.  All increases in transaminase values 
were less than twofold.  Although he had increases in bilirubin while on indinavir, 
his highest total bilirubin was 1.6 mg/dL.  Also, this subject developed leukopenia 
(1.7 x 109/L from baseline of 5.3 x 109/L), decreased circulating neutrophils 
(prestudy, 51%; post-dose, 8%) and decreased circulating platelets (prestudy, 235 
x 109/L; post-dose, 137 x 109/L) while on indinavir and rifabutin.  Following 8 days 
off drug his circulating leukocytes, neutrophils, and platelets returned to within 
normal limits.  The second subject had increases in transaminases; AST and ALT 
while on indinavir alone and increases in AST while on rifabutin alone.  All increases 
were less than twofold.  
In Study 2, 5 of 10 subjects had clinical adverse experiences judged by the 
investigator to be drug-related.  Of these drug-related clinical adverse experience, 
one subject experienced  upper respiratory infection symptoms while on indinavir 
and rifabutin, one subject had mild abdominal pain while on combination therapy, 
one subject developed vaginitis while on rifabutin alone, and one subject had a 
change in bowel patterns on rifabutin and dyspepsia while on indinavir and a fifth 
subject was discontinued for a rash judged as probably related to treatment while 
on indinavir and rifabutin 150 mg.  
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Four of 5 subjects had drug-related laboratory adverse experiences.  Two subjects 
had increases in transaminases; one subject had an increase in AST (< 3 fold) 
while on indinavir and rifabutin 150 mg and one subject had increases in AST and 
ALT while on rifabutin 300 mg alone  (a transient 5 -fold increase which decreased 
to ~ 2 fold  within 2 days).  Two subjects had decreases in circulating neutrophils 
which were possibly related to study drug.  One had a decrease in circulating 
neutrophils of 34% (with a total WBC of 3.3) during washout (4 days following 
completion of Period 2, rifabutin 300 mg alone) and was discontinued.  Within 8 
days, his circulating neutrophils returned to within normal limits at 61% (with a total 
WBC of 5.0).  The other subject experienced decreases in circulating neutrophils 
of 34% (with a total WBC of 3.4) on Day 11, Period 2 while on rifabutin 300 mg 
alone.  Within 7 days, his neutrophils returned to within normal limits at 48%, and 
he completed the study.   
Discussion 
All HIV protease inhibitors currently approved for clinical use, including indinavir, 
are metabolized by the CYP3A4 isoenzymes.  Indinavir inhibits CYP3A4, whereas 
rifabutin induces CYP3A4.  Given the simultaneous inhibition and induction of 
CYP3A4 following coadministration of these two drugs, prediction of proper dosing 
schedules for combined therapy is challenging.  The standard dose schedule of 
indinavir is 800 mg q8h, while the standard dose of rifabutin for MAC prophylaxis is 
300 mg daily.16,17  When administered to healthy subjects, this combination led to 
a 44% decrease in the geometric mean AUC(0-8h) of indinavir compared to indinavir 
administered alone, presumably reflecting induction of indinavir metabolism by 
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rifabutin and/or its active metabolite.  Conversely, this combination resulted in a 
rifabutin AUC(0-24h) that was 2.7-fold higher compared to rifabutin administered 
alone, presumably reflecting inhibition of CYP3A4 by indinavir.  Similarly, this 
interaction likely contributed to the 4.8-fold increase observed in 25-desacetyl 
rifabutin AUC(0-24h), the most abundant urinary metabolite of rifabutin18, when 
rifabutin and indinavir were coadministered.  This metabolite has equivalent 
antibacterial activity to rifabutin, but normally achieves a 10-fold lower 
concentration in the serum compared to the parent drug.11  Since this compound is 
found at a concentration one log lower than the parent compound, the clinical 
implication of the differential increase is likely minor.  
The greater than 30% decrease in geometric mean plasma indinavir AUC and 
trough concentration when coadministered with rifabutin, compared to indinavir 
alone, is likely clinically important.  Concentrations of protease inhibitor which are 
sub-therapeutic select for drug-resistant virus and eventually lead to failure of the 
treatment.19  This occurs despite the fact that such drug-resistant viruses tend to 
be less virulent.20  The goal of a rational schedule for dosing with indinavir is to 
maintain antiviral efficacy.  In a similar fashion, supra-therapeutic concentrations of 
rifabutin found in Study 1 might be expected to increase the incidence of 
concentration-dependent side effects. 
Because pharmacokinetic interactions between indinavir and rifabutin were 
observed in Study 1, Study 2 was conducted in which rifabutin was administered at 
one half the standard daily dose (150 mg) in combination with indinavir and rifabutin 
300 mg alone was used as the reference arm.  Note that the predication was that 
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150 mg rifabutin with indinavir would have a similar exposure to 300 mg rifabutin 
when used alone.  In this study, the dose of indinavir was not increased because it 
was presumed that induction of CYP3A4 by lower doses of rifabutin would have a 
smaller impact on circulating indinavir concentrations.  Surprisingly, the AUC and 
the geometric mean ratio of the AUC of indinavir when administered with rifabutin 
300 mg and 150 mg were nearly identical.  That plasma concentrations of indinavir 
were decreased by the same magnitude with full doses (300 mg) and reduced 
doses (150 mg) of rifabutin suggests that both doses of rifabutin induced the 
metabolism of indinavir by CYP3A4 to a similar extent.  In contrast, administration 
of rifabutin 150 mg daily with indinavir resulted in circulating rifabutin concentrations 
that were 1.54-fold higher of those achieved by administering rifabutin 300 mg 
alone.  This is substantially less than the 2.73-fold increase in geometric mean 
rifabutin AUC when 300 mg daily of rifabutin was administered with indinavir. 
Treatments administered in these studies were generally well-tolerated without a 
clear difference in the pattern of adverse experiences observed during combination 
therapy and monotherapy.  The laboratory experiences, for study 1 and 2, 
appeared to indicate the leukopenia/neutropenia was occurring with rifabutin 300 
mg alone and rifabutin 300 mg and indinavir.  Neutropenia may be associated with 
the use of rifabutin and therefore, possible increases in rifabutin concentrations 
when coadministered with indinavir may have contributed to the laboratory adverse 
experience in the healthy subject in study 1 
The limitations imposed by available rifabutin dosage strength, coupled with the 
lack of efficacy data for alternate day dosing, suggest that the modest increase in 
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rifabutin concentrations noted in study 2 are in a range that would maintain efficacy 
with reasonable safety.  In contrast, the need to avoid a subtherapeutic indinavir 
concentration suggests the requirement of a higher indinavir dose when 
coadministered with rifabutin.  Therefore, the results described herein resulted in a 
subsequent study sponsored by the AIDS Clinical Trials Group (ACTG 365) in 
which the regimen of indinavir 1000 mg q8h and rifabutin 150 mg daily was 
evaluated in healthy volunteers and HIV seropositive patients.21  In this study, 
systemic exposure of indinavir was similar between 800 mg administered alone and 
1000 mg administered with 150 mg rifabutin.  Rifabutin concentrations were 
increased by 70%.  These pharmacokinetic observations are the basis of the 
present recommendation of indinavir 1000mg q8 hr when coadministered with 
rifabutin at 150 mg q24 hr.22  However, the clinical importance of the increase in 
rifabutin remains unknown. 
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Tables 
 
Table I. Geometric means, geometric mean ratios and 90% confidence intervals 
of indinavir administered with and without rifabutin 300 mg daily. 
 
Indinavir 
Measurement 
Geometric 
mean without 
rifabutin 300 
mg 
Geometric 
mean with 
rifabutin 300 
mg 
Geometric 
mean ratio 
combination/ 
monotherapy 
90% CI 
AUC(0-8h) 
(nM●h) 
27231.4 17984.9 0.66 (0.56, 0.77) 
Cmax (nM) 14438.9 10764.6 0.75 (0.61, 0.91) 
C8 h (nM) 162.4 99.1 0.61 (0.50, 0.75) 
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Table II. Geometric means, geometric mean ratios and 90% confidence intervals 
of rifabutin and 25-desacetyl rifabutin when rifabutin is administered at 300 mg qd 
with and without indinavir. 
 
Pharmacokinetic 
Parameter 
Geometric 
mean 
without 
indinavir 
Geometric 
mean with 
indinavir 
Geometric mean 
ratio combination/ 
monotherapy 
90% CI 
Rifabutin measurement 
AUC(0-24h) 
(ng●h/mL) 
2562.8 7006.7 2.73 (1.99, 3.77) 
Cmax (ng/mL) 292.8 686.2 2.34 (1.64, 3.35) 
25-desacetyl rifabutin measurement 
AUC(0-24h) 
(ng●h/mL) 
166.7 793.0 4.76 (3.07, 7.36) 
Cmax (ng/mL) 22.7 80.9 3.56 (2.46, 5.16) 
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Table III. Geometric means, geometric mean ratios and 90% confidence intervals 
of indinavir concentration administered alone and in combination with rifabutin 
150 mg daily. 
 
Indinavir 
Measurement 
Geometric 
mean without 
rifabutin  
Geometric 
mean with 
rifabutin 150 mg 
Geometric mean 
ratio combination/ 
monotherapy 
90% CI 
AUC(0-8h) (nM●hr) 27340.1 18483.6 0.68 (0.60, 0.76) 
Cmax (nM) 12169.7 9729.6 0.80 (0.72, 0.89) 
C8h (nM) 147.9 89.2 0.60 (0.51, 0.72) 
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Table IV. Geometric means geometric mean ratios and 90% confidence intervals 
for rifabutin and 25-desacetyl rifabutin following rifabutin 300 mg alone and 
rifabutin and 25-desacetyl rifabutin following rifabutin 150 mg in combination with 
indinavir.  
 
Pharmacokinetic 
Parameter 
Geometric 
mean 300 mg 
rifabutin alone 
Geometric 
mean rifabutin 
150 mg with 
indinavir 
Geometric 
mean ratio 
combination/ 
monotherapy 
90% CI 
Rifabutin measurement 
AUC(0-24h) (ng●h/mL) 2866.0 4422.2 1.54 (1.33, 1.79) 
Cmax (ng/mL) 289.4 374.0 1.29 (1.05, 1.59) 
25--desacetyl rifabutin measurement 
AUC(0-24h) (ng●h/mL) 130.7 529.9 4.05 (2.92, 5.64) 
Cmax (ng/mL) 18.7 45.6 2.43 (2.00, 2,95) 
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Legends for Figures 
 
Figure 1:  Mean (SE) plasma concentrations of Indinavir after oral administration 
of indinavir 800 mg q8h alone and in combination with  300 mg rifabutin  for 10 
days (n=10). 
 
Figure 2: Mean (SE) plasma concentrations of rifabutin after oral administration of 
300 mg rifabutin daily alone and in combination with indinavir 800 mg q8h for 10 
days (n=10). 
 
Figure 3: Mean (SE) plasma concentrations of 25-desacetyl-rifabutin after oral 
administration of 300 mg rifabutin daily alone and in combination with indinavir 
800 mg q8h for 10 days (n=10). 
 
Figure 4: Mean (SE) plasma concentrations of Indinavir after oral administration of 
indinavir 800 mg q8h alone and in combination with 150 mg rifabutin (n=14). 
 
Figure 5: Mean (SE) plasma concentrations of rifabutin after oral administration of 
300 mg rifabutin daily alone or 150 mg rifabutin daily in combination with indinavir 
800 mg q8h for 10 days (n=14). 
 
Figure 6: Mean (SE) plasma concentrations of 25-desacetyl-rifabutin after oral 
administration of 300 mg rifabutin daily alone or 150 mg rifabutin daily in 
combination with  indinavir 800 mg q8h for 10 days (n=14). 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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